In some clinical applications in oncology randomized, double armed, and double-blind trials are not possible. In case of device applications, double-blinded conditions are nonrealistic, and with many times the randomization also has complications due to the high-line treatments where the reference cohort is not available; the active “arm” has mainly palliative initiative. Sometimes highly personalized therapies block the collection of the homogeneous group and limit its double-arm randomization. Our objective is to discuss the situations of the single arm evaluation and to give methods for the mining of information from this to increase the level of evidence of the measured dataset. The basic idea of the data-separation is the appropriate parameterization of the non-parametric Kaplan-Meier survival pattern by the poly-Weibull fit.
KeywordsSingle-Arm Clinical TrialSurvival-TimeDecomposition of Survival CurvesPersonalized TreatmentObservational Trial
Enderling, H., Hahnfeldt, P., Hlatky, L. and Almog, N. (2012) Systems Biology of Tumor Dormancy: Linking Biology and Mathematics on Multiple Scales to Improve Cancer Therapy. Cancer Research, 72, 2172-2175. https://doi.org/10.1158/0008-5472.CAN-11-3269
Szasz, O., Vincze, Gy., Szigeti, Gy.P., Benyo, Z. and Szasz, A. (2018) An Allometric Approach of Tumor-Angiogenesis. Medical Hypothesis, 116, 74-78. https://doi.org/10.1016/j.mehy.2018.03.015
Hubbard, M.O., Pingfu, F., Margevicius, S., Dowlati, A. and Linden, P.A. (2012) Five-Year Survival Does Not Equal Cure in Non-Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results-Based Analysis of Variables Affecting 10- to 18-Year Survival. The Journal of Thoracic and Cardiovascular Surgery, 143, 1307-1313. https://doi.org/10.1016/j.jtcvs.2012.01.078
Manton, K.G., Akushevich, I. and Kravchenko, J. (2009) Cancer Mortality and Morbidity Patters in the U.S. Population. Springer, Science + Business Media, New York. https://doi.org/10.1007/978-0-387-78193-8
Kodish, E., Lantos, J.D. and Siegler, M. (1991) The Ethics of Randomization. Cancer Journal for Clinicians, 41, 180-187. https://doi.org/10.3322/canjclin.41.3.180
Goldstein, C.E., Weijer, C., Brehaut, J.C., Fergusson, D.A., Grimshaw, J.M., Horn, A.R. and Taljaard, M. (2017) Ethical Issues in Pragmatic Randomized Controlled Trials: A Review of the Recent Literature Identifies Gaps in Ethical Argumentation. BMC Medical Ethics, 19, Article No. 14. https://doi.org/10.1186/s12910-018-0253-x
Meulemeester, J.D., Fedyk, M., Jurkovic, L., Reaume, M., Dowlatshahi, D., Stotts, G. and Shamy, M. (2018) Many Randomized Clinical Trials May Not Be Justified: A Cross-Sectional Analysis of the Ethics and Science of Randomized Clinical Trials. Journal of Clinical Epidemiology, 97, 20-25. https://doi.org/10.1016/j.jclinepi.2017.12.027
Odaimi, M. and Ajani, J. (1987) High-Dose Chemotherapy. Concepts and Strategies. American Journal of Clinical Oncology, 10, 123-132. https://doi.org/10.1097/00000421-198704000-00045
Lilford, R.J. and Jackson, J. (1995) Equipoise and the Ethics of Randomization. The Journal of the Royal Society of Medicine, 88, 552-559.
Ellenberg, S.S. and Joffe, S. (2017) Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives. The Journal of Law, Medicine & Ethics, 45, 375-381. https://doi.org/10.1177/1073110517737538
Hatswell, A.J., Thompson, G.J., Maroudas, P.A., Sofrygin, O. and Delea, T.E. (2017) Estimating Outcomes and Cost Effectiveness Using a Single-Arm Clinical Trial: Ofatumumab for Double-Refractory Chronic Lymphocytic Leukemia. Cost Effectiveness and Resource Allocation, 15, 8. https://doi.org/10.1186/s12962-017-0071-x
Hirakawa, A., Nishikawa, T., Yonemori, K., Shibata, T., Nakamura, K., Ando, M., Ueda, T., Ozaki, T., Tamura, K., Kawai, A. and Fujiwara, Y. (2017) Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Therapeutic Innovation & Regulatory Science, 51, 207-211. https://doi.org/10.1177/2168479017728989
DeMets, D., Friedman, L. and Furberg, C. (2010) Fundamentals of Clinical Trials. 4th Edition, Springer, Berlin. https://doi.org/10.1007/978-1-4419-1586-3_1
Camazine, S., Deneubourg, J.L., Franks, N.R., et al. (2003) Self-Organization in Biological Systems. Princeton Studies in Complexity, Princeton Univ. Press, Princeton, Oxford.
Bassingthwaighte, J.B., Leibovitch, L.S. and West, B.J. (1994) Fractal Physiology. Oxford Univ. Press, New York, Oxford. https://doi.org/10.1007/978-1-4614-7572-9
Kurakin, A. (2011) The Self-Organizing Fractal Theory as a Universal Discovery Method: The Phenomenon of Life. Theoretical Biology and Medical Modelling, 8, 4. https://doi.org/10.1186/1742-4682-8-4
Scheffer, M. and Nes, E.H. (2006) Self-Organized Similarity, the Evolutionary Emergence of Groups of Similar Species. PNAS, 103, 6230-6235. https://doi.org/10.1073/pnas.0508024103
West, G.B., Woodruf, W.H. and Brown, J.H. (2002) Allometric Scaling of Metabolic Rate from Molecules and Mitochondria to Cells and Mammals. Proceedings of the National Academy of Sciences of the United States of America, 99, 2473-2478. https://doi.org/10.1073/pnas.012579799
West, G.B. and Brown, J.H. (2000) Scaling in Biology. Oxford University Press, Oxford.
West, G.B., Brown, J.H. and Enquist, B.J. (2001) A General Model for Ontogenetic Growth. Nature, 413, 628-631. https://doi.org/10.1038/35098076
Pugno, N.M. (2005) On the Statistical Law of Life. Department of Structural Engineering, Politecnico di Torino, Corso Duca degli Abruzzi.
Bru, A., Albertos, S., Subiza, J.L., García-Asenjo, J.L. and Bru, I. (2003) The Universal Dynamics of Tumor Growth. Biophysical Journal, 85, 2948-2961. https://doi.org/10.1016/S0006-3495(03)74715-8
Guiot, C., Degiorgis, P.G., Delsanto, P.P., Gabriele, P. and Deisboeck, T.S. (2003) Does Tumor Growth Follow a “Universal Law”? Journal of Theoretical Biology, 225, 147-151. https://doi.org/10.1016/S0022-5193(03)00221-2
Szasz, O., Szigeti, G.P. and Szasz, A. (2019) The Intrinsic Self-Time of Biosystems. Open Journal of Biophysics, 9, 131-145.
Nadler, D.L. and Zurbenko, I.G. (2013) Developing a Weibull Model Extension to Estimate Cancer Latency. ISRN Epidemiology, 2013, Article ID: 750857. https://doi.org/10.5402/2013/750857
Szasz, O., Szigeti, G.P. and Szasz, A. (2017) On the Self-Similarity in Biological Processes. Open Journal of Biophysics, 7, 183-196. https://doi.org/10.4236/ojbiphy.2017.74014
Szasz, O. and Szasz, A. (2019) Parametrization of Survival Measures, (Part I), Consequences of Self-Organizing. International Journal of Clinical Medicine. (In Press)
Case, L.D. and Morgan (2003) Design on Phase II Cancer Trials Evaluating Survival Probabilities. BMC Medical Research Methodology, 3, 6-18. https://doi.org/10.1186/1471-2288-3-6
Joshnson, W.A. and Mehl, P.A. (1939) Reaction Kinetics in Processes of Nucleation and Growth. Transactions of the American Institute of Mining and Metallurgical Engineers, 135, 416-442.
Avrami, M.A. (1939) Kinetics of Phase Change, Part I: Kinetics of Phase Change. I. General theory. The Journal of Chemical Physics, 7, 1103.
Avrami, M.A. (1940) Kinetics of Phase Change, Part II: Kinetics of Phase Change. II. Transformation-Time Relations for Random Distribution of Nuclei. The Journal of Chemical Physics, 8, 202.
Avrami, M.A. (1941) Kinetics of Phase Change, Part III: Phase Change and Microstructure Kinetics of Phase Change. The Journal of Chemical Physics, 9, 177.
Levine, L.E., Lakshimi Narayan, K. and Kelton, K.F. (1997) Finite Size Corrections for the Johnson-Mehl-Avrami-Kolmogorov Equation. Journal of Materials Research, 12, 124-131. https://doi.org/10.1557/JMR.1997.0020
Cope, F.W. (1976) The Kinetics of Biological Phase Transitions Manifested by Sigmoid Time Curves: A Review of Approaches. Physiological Chemistry and Physics, 8, 519-527.
Pham, H. (2008) Mortality Modeling Perspectives. In: Pham, H., Ed., Recent Advances in Reliability and Quality in Design, Springer, Berlin, Ch. 25, 509-516. https://doi.org/10.1007/978-1-84800-113-8_25
Wilson, D.L. (1994) The Analysis of Survival (Mortality) Data: Fitting Gompertz, Weibull, and Logistic Functions. Mechanisms of Ageing and Development, 74, 15-33. https://doi.org/10.1016/0047-6374(94)90095-7
Juckett, D.A. and Rosenberg, B. (1993) Comparison of the Gompertz and Weibull Functions as Descriptors for Human Mortality Distributions and Their Intersections. Mechanisms of Ageing and Development, 69, 1-31. https://doi.org/10.1016/0047-6374(93)90068-3
Ricklefs, R.E. and Scheuerlein, A. (2002) Biological Implications of the Weibull and Gompertz Models of Aging. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 57, B69-B76. https://doi.org/10.1093/gerona/57.2.B69
Tyurin, Yu.N., Ykovlev, A.Yu., Shi, J., et al. (1995) Testing a Model of Aging in Animal Experiments. Biometrics, 51, 363-372. https://doi.org/10.2307/2533345
Vanfleteren, J.R., De Vreese, A. and Braeckman, B.P. (1998) Two-Parameter Logistic and Weibull Equations Provide Better Fits to Survival Data from Isogenic Populations of Caenorhabditis elegans in Axenic Culture than Does the Gompertz Model. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 53, B393-B403. https://doi.org/10.1093/gerona/53A.6.B393
EL-Damcese, M.A., Mustafa, A. and Eliwa, M.S. (2015) Exponentaited Generalized Weibull Gompertz Distribution. https://doi.org/10.4236/am.2015.614206 https://arxiv.org/ftp/arxiv/papers/1412/1412.0705.pdf
Zhang, X.X., Fröhlich, H., Grigoriev, D., Vakulenko, S., Zimmermann, J. and Weber, A.G. (2018) A Simple 3-Parameter Model for Cancer Incidences. Scientific Reports, 8, Article No. 3388. https://doi.org/10.1038/s41598-018-21734-x
Sposto, R. (2002) Cure Model Analysis in Cancer: An Application to Data from the Children’s Cancer Group. Statistics in Medicine, 21, 293-312. https://doi.org/10.1002/sim.987
Sposto, R. (2007) Criteria for Optimizing Prognostic Risk Groups in Pediatric Cancer: Analysis of Data from the Children’s Oncology Group. Journal of Clinical Oncology, 25, 2070-2077. https://doi.org/10.1200/JCO.2006.09.1983
Frankel, P. and Longmate, J. (2009) Parametric Models for Accelerated and Long-Term Survival: A Comment on Proportional Hazards. Statistics in Medicine, 21, 3279-3289. https://doi.org/10.1002/sim.1273
Schultz, K.R., Pullen, D.J., Sather, H.N., Shuster, J.J., Devidas, M., et al. (2007) Risk- and Response-Based Classification of Childhood B-Precursor Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood, 109, 926-935.
Jones, E., Dewhirst, M. and Vujaskovic, Z. (2003) Hyperthermia Improves the Complete Response Rate for Superficial Tumors Treated with Radiation: Results of a Prospective Randomized Trial Testing the Thermal Dose Parameter CEM 43°T90. International Journal of Radiation Oncology, Biology, Physics, 57, S253-S254. https://doi.org/10.1016/S0360-3016(03)01088-5
Weinberg, R.A. (1998) One Renegate Cell: How Cancer Begins. Science Master Series, Basic Books, New York.
Welch, H.G. and Schwartz, L.M. (2000) Are Increasing 5-Year Survival Rates Evidence of Success against Cancer? JAMA, 283, 2975-2978. https://doi.org/10.1001/jama.283.22.2975
Zelek, S.H. (1998) On Understanding the Hardin Jones-Pauling Biostatistical Theory of Survival Analysis for Cancer Patients. The Journal of Orthomolecular Medicine, 13, 1-12.
Zelek, S.H. (1998) The Application of the Hardin Jones-Pauling Biostatistical Theory of Survival Analysis for Cancer Patients to a Clinical Trial Purporting to Test the Efficacy of Vitamin C in Lengthening the Survival Times of Patients with Advanced Colorectal Cancer. The Journal of Orthomolecular Medicine, 13, 225-232.
Cover, T.M. and Thomas, J.A. (2005) Elements of Information Theory. Wiley, Hoboken. https://doi.org/10.1002/047174882X